The ARHGAP39 Knockout HT29 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma line, carrying a targeted disruption of the ARHGAP39 gene. This loss-of-function model enables potent inhibition of ARHGAP39 protein expression, providing a robust tool for dissecting the gene??s role in Rho GTPase signaling. As a polyclonal population, the pool contains a mixture of edited alleles, reflecting the heterogeneous nature of CRISPR-mediated gene knockout and offering a practical system for initial functional screening without the need for single-cell cloning.
The parental HT29 cell line is a widely used epithelial model isolated from a 44-year-old female with colorectal adenocarcinoma. These adherent cells retain characteristics of colon epithelia and have become a standard platform for drug absorption studies, cancer biology research, and investigations into colorectal tumorigenesis. HT29 cells harbor mutations in key oncogenic pathways, making them a relevant host for evaluating the impact of ARHGAP39 loss on malignant phenotypes in a colorectal cancer background.
ARHGAP39 encodes a GTPase-activating protein (GAP) that specifically accelerates the intrinsic GTP hydrolysis of Rho family GTPases RhoA, Rac1, and Cdc42, thereby converting them from active GTP-bound to inactive GDP-bound states. This activity places ARHGAP39 as a negative regulator of these central molecular switches. The protein is activated downstream of growth factor receptors, including those for EGF, HGF, and PDGF, as well as integrin?CFAK signaling. By inactivating RhoA, Rac1, and Cdc42, ARHGAP39 suppresses downstream effectors such as ROCK and PAK, leading to reduced phosphorylation of myosin light chain (MLC) and cofilin, decreased actin stress fiber assembly, and enhanced focal adhesion turnover. This cascade further attenuates signaling through myosin light chain kinase (MLCK) and profilin, thereby limiting actin polymerization and actomyosin contractility. ARHGAP39 interacts with cortactin, c-Src, and filamin A (FLNA) to fine-tune actin cytoskeletal dynamics and cell migration.
In the HT29 colorectal adenocarcinoma context, loss of ARHGAP39 function is predicted to increase active RhoA, Rac1, and Cdc42 levels, thereby promoting actin polymerization, focal adhesion maturation, and cell motility. This makes the knockout model particularly useful for dissecting molecular mechanisms underlying enhanced tumor cell migration and invasion??key steps in metastasis. Moreover, the interplay between ARHGAP39 and upstream regulators such as integrin-mediated adhesion and growth factor signaling can be directly examined, providing insight into how extracellular cues are transduced to cytoskeletal rearrangements in colon cancer cells. The model thus serves as a platform for understanding metastatic drivers and for testing interventions that target the Rho GTPase signaling axis.
Typical applications include performing wound-healing and transwell invasion assays to quantify changes in motility and invasive capacity, combined with Rho GTPase activity pull-downs (G-LISA) to assess the activation state of RhoA, Rac1, and Cdc42. Western blotting for phospho-MLC and cofilin can corroborate altered downstream signaling, while immunofluorescence staining of F-actin reveals structural alterations in the actin cytoskeleton. RT-qPCR validation of ARHGAP39 knockdown and cell adhesion assays provide complementary functional readouts. Researchers can employ this model to screen anti-metastatic compounds, study Rho GTPase dynamics in colorectal cancer, and explore the fundamental biology of cell migration. For further information or to inquire about this product, please contact Ascent Research.
